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lStamou and colleagues present another critical article
about adverse outcome following administration of aprotinin
in adult cardiac surgery [1]. In this retrospective study,
haemostatic effects of aprotinin were confirmed but the
authors found an increased risk for in-hospital cardiac arrest.
Another intriguing finding was found, namely that the risk of
late cardiac death was higher in patients who received
aprotinin than after aminocaproic acid (EACA). Unfortu-
nately, neither the cause of early mortality nor the problem
of cardiac-related attrition (graft occlusion, perioperative
myocardial infarction, malignant arrhythmias or others) were
analysed or specified.
Because of the retrospective character of the study,
several limitations and bias have to be considered: the use of
aprotinin or EACA was left at the discretion of the surgeons.
The patients who received aprotinin were older, had more
prior surgery, suffered more frequently from congestive
heart failure (NYHA class IV) and underwent more often
complex and emergency surgery than those who received
EACA. It is questionable if propensity score matching may be
sufficient to eliminate ‘confounding by treatment’ differ-
ences of the two study groups. The authors conclude that the
risk of aprotinin may not be worth the benefit of reduced
transfusion requirements.
There are a tremendous number of publications dealing
with aprotinin, but a single finding seems to be consistent:
aprotinin is associated with decreased transfusion require-
ment and re-exploration rate because of bleeding. This was
already the main finding of the initial report of Royston and
colleagues [2]. Inmore recent years, the question appeared if
aprotinin increases the risk of renal dysfunction and is an
independent predictor of increased mortality. Concerning
the last two end-points, conflicting results are present in
literature.
The two most important ‘negative’ trials for aprotinin
(Mangano et al. [3] as well as the Bart trial [4]) have beenargely discussed in literature. Not only the power but also
he limitations of these trials are very well pointed out. Some
uthors believe that the recent ‘attacks’ against aprotinin
ay have been statistically unsound [5]. Even extensive
eta-analysis of the Cochrane collaboration in 2007 have not
ound an increased risk of death caused by the use of
protinin compared to lysine analogues. The use of aprotinin
as recommended especially in high-risk patients in whom a
ubstantial blood loss has to be expected [6]. In amore recent
pdate, this option has been contradicted by the same
uthors [7].
What are the remaining questions? There has been an
ncreasing concern that questions the safety of aprotinin. If
e accept this, we are forced to ask why this was not
etected during the two decades of extensive use of the drug
ith published good results. As a result of the aprotinin story
8], studies should — if ever possible — focus on clinical end-
oints that are not confounded with surrogate markers.
ndependent clinical safety studies are mandatory even after
egulatory approval.
Unfortunately, the large majority of studies that demon-
trated adverse outcome following aprotinin were performed
sing the original Hammersmith protocol, whichmeans a high
osage. More than 15 years ago, we published similar
eneficial haemostatic results with low-dose aprotinin and no
dverse cardiac outcomewas observed, neither early nor late
9]. We do not understand why the low-dose regime was not
dopted by more institutions.
Finally, it is today still not clear which patient subgroups
ay benefit from aprotinin. However, this is more of
heoretical interest since the drug is no longer available
n a regular basis. Considering that low-risk cardiac surgical
atients are at increased risk for bleeding events (e.g.,
aving operation under ongoing combined anti-platelet
herapy), other potent measures in addition to the available
ysine analogues in order to reduce postoperative bleeding,
S.C. Stamou et al. / European Journal of Cardio-thoracic Surgery 36 (2009) 869—876876the need for transfusion and the incidence of haemorrhagic
re-exploration are welcome.
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